These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28779511)

  • 1. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
    Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
    Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice.
    Velazquez R; Meechoovet B; Ow A; Foley C; Shaw A; Smith B; Oddo S; Hulme C; Dunckley T
    Mol Neurobiol; 2019 Dec; 56(12):8364-8375. PubMed ID: 31240602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
    Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
    J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.
    Caccamo A; Branca C; Talboom JS; Shaw DM; Turner D; Ma L; Messina A; Huang Z; Wu J; Oddo S
    J Neurosci; 2015 Oct; 35(41):14042-56. PubMed ID: 26468204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
    Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
    Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7.
    Chu D; Lei L; Gu S; Liu F; Wu F
    Biochem Pharmacol; 2024 Jun; 224():116233. PubMed ID: 38663682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
    Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
    Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.
    Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA
    J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease.
    Shen Y; Hua L; Yeh CK; Shen L; Ying M; Zhang Z; Liu G; Li S; Chen S; Chen X; Yang X
    Theranostics; 2020; 10(25):11794-11819. PubMed ID: 33052247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.
    Yang JT; Wang ZJ; Cai HY; Yuan L; Hu MM; Wu MN; Qi JS
    Neurosci Bull; 2018 Oct; 34(5):736-746. PubMed ID: 30099679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Li JG; Praticò D
    PLoS One; 2013; 8(8):e70991. PubMed ID: 23951061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
    Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
    Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.